Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. ADC Market Outlook to 2022
    4.1 ADCETRIS
          4.1.1 Market Potential
          4.1.2 Market Size and Forecast to 2022
    4.2 Kadcyla
           4.2.1 Market Potential
           4.2.2 Market Size and Forecast to 2022

5. ADC Pipeline Analysis
     5.1 By Companies
            5.1.1 By Clinical Phase
            5.1.2 By Indication
            5.1.3 By Drug
            5.1.4 By Type of Linker
            5.1.5 By Mode of Action
            5.1.6 By Technology
     5.2 By Research Organizations
            5.2.1 By Phase
            5.2.2 By Indication
            5.2.3 By Drug
            5.2.4 By Type of Linker
            5.2.5 By Mode of Action

6. Drivers and Challenges
    6.1 Drivers
         6.1.1 Rising Global Cancer Epidemics
         6.1.2 Advances in Linking Technologies Re-Instills Hope in ADC
         6.1.3 Efforts towards Patent Protection to Drive ADC Market
         6.1.4 Increasing Demand for Antibody Drug Conjugates
    6.2 Challenges
          6.2.1 Production Hurdles and Cost
          6.2.2 Inadequacy of Experienced Manufacturers
          6.2.3 Regulatory Challenges

7. Major Potential ADCs in Pipeline
    7.1 By Companies
          7.1.1 Glembatumumab Vedotin Therapeutics /CDX-011 - Celldex
          7.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc.
          7.1.3 Indatuximab Ravtansine/BT-062 - Biotest
          7.1.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
          7.1.5 Polatuzumab Vedotin/RG7596 - Roche Genentech
          7.1.6 DMUC-4064A/RG7882 - Roche Genentech
          7.1.7 Mirvetuximab Soravtansine/IMGN853 - ImmunoGen Inc.
          7.1.8 Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium
    7.2 By Research
          7.2.1 SGM-101 – SurgiMab in Collaboration with Center for Human Drug Research, Netherlands
          7.2.2 Panitumumab-IRDye800 – Eben Rosenthal/Stanford University
          7.2.3 90Yttrium Ibritumomab Tiuxetan (Zevalin) – Biogen Idec in Collaboration with Soroka University Medical Center
          7.2.4 MOC31-PE – Creative Biolabs in Collaboration with Oslo University Hospital

8. Trends and Developments
    8.1 ADC at the Forefront of Treating Hematological Malignancies
    8.2 ADCs Proving Advantageous for Breast Cancer Patients

9. Strategic Collaborations in the ADC Industry

10. Competitive Assessment
     10.1 Seattle Genetics, Inc.
     10.2 F. Hoffman-La Roche Ltd.
     10.3 ImmunoGen, Inc.
     10.4 Bayer AG
     10.5 Novartis AG
     10.6 Takeda Pharmaceutical Company Limited
     10.7 Immunomedics, Inc.
     10.8 Agensys, Inc.
     10.9 Concortis Biotherapeutics
     10.10 NBE-Therapeutics